Henlius has no confirmed US launch yet among the blockbuster drugs on this tracker, holds FDA approval for 3 of them, and has 2 filed or in development. Those brands earned $56.1B in 2025. Of the 70 makers we follow, 17 are lined up to copy more of these drugs.
| Drug | Henlius' status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Prolia BildyosBiosimilar · Amgen · US LOE 2025 | FDA-approved 29 Aug 2025; interchangeable | 7 on sale · 2 approvedof 10 other makers listed | $4.4B |
| Xgeva BilprevdaBiosimilar · Amgen · US LOE 2025 | FDA-approved 29 Aug 2025; interchangeable | 6 on sale · 3 approvedof 10 other makers listed | $2.1B |
| Perjeta PoherdyBiosimilar · Roche · US LOE 2026 | FDA-approved 13 Nov 2025; interchangeable; first interchangeable biosimilar; exclusivity as the only interchangeable, end date not yet set by the FDA With Organon |
0 on sale · 0 approvedof 1 other maker listed | ≈$3.6B |
| Drug | Henlius' status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| KeytrudaBiosimilar · Merck · US LOE 2028 | In clinical trials | 0 on sale · 0 approvedof 9 other makers listed | $31.7B |
| Darzalex HLX15Biosimilar · Johnson & Johnson · US LOE 2029 | In clinical trials. First patient dosed May 2026 With Dr. Reddy's |
0 on sale · 0 approvedof 1 other maker listed | $14.3B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
Each row is a copy Henlius sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Henlius' full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Henlius' sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Yahoo Finance.